ConductScience.org, home

Paper38770366

Remdesivir versus Favipiravir in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia: A Propensity Score-Matched Retrospective Cohort Study.

Chavalertsakul K and 6 others. Int J Gen Med, 2024. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Remdesivir versus Favipiravir in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia: A Propensity Score-Matched Retrospective Cohort Study. Papers, record 38770366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38770366

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Remdesivir versus Favipiravir in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia: A Propensity Score-Matched Retrospective Cohort Study.
PubMed
Journal
Int J Gen Med
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
2
iCite
Relative citation ratio, by iCite
0.22, provisional
iCite
Revised in PubMed
2025-01-04
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chavalertsakul KKaruna
2Sutherasan YYudahttps://orcid.org/0000-0003-1754-0962
3Petnak TTananchai
4Thammavaranucupt KKanin
5Kirdlarp SSuppachok
6Boonsarngsuk VViboon
7Sungkanuparph SSomnuek

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References26

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129891600Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses.Antimicrob Agents Chemother2018https://conductscience.org/library/papers/29891600PubMed
234040117The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.Sci Rep2021https://conductscience.org/library/papers/34040117PubMed
337589788Remdesivir: A Review in COVID-19.Drugs2023https://conductscience.org/library/papers/37589788PubMed
436776761Effectiveness of Favipiravir monotherapy in the treatment of COVID-19: real world data analysis from Thailand.Lancet Reg Health Southeast Asia2023https://conductscience.org/library/papers/36776761PubMed
532423584Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.Lancet2020https://conductscience.org/library/papers/32423584PubMed
634937145Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.N Engl J Med2022https://conductscience.org/library/papers/34937145PubMed
737556727Remdesivir Reduced Mortality in Immunocompromised Patients Hospitalized for COVID-19 Across Variant Waves: Findings From Routine Clinical Practice.Clin Infect Dis2023https://conductscience.org/library/papers/37556727PubMed
833306283Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.N Engl J Med2021https://conductscience.org/library/papers/33306283PubMed
935474740Antiviral agents for the treatment of COVID-19: Progress and challenges.Cell Rep Med2022https://conductscience.org/library/papers/35474740PubMed
1036635036Inter-rater reliability and prognostic value of baseline Radiographic Assessment of Lung Edema (RALE) scores in observational cohort studies of inpatients with COVID-19.BMJ Open2023https://conductscience.org/library/papers/36635036PubMed
1135639525Favipiravir Treatment of Uncomplicated Influenza in Adults: Results of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials.J Infect Dis2022https://conductscience.org/library/papers/35639525PubMed
1222446091Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides.Bioorg Med Chem Lett2012https://conductscience.org/library/papers/22446091PubMed
1335308532Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia.Front Med (Lausanne)2022https://conductscience.org/library/papers/35308532PubMed
1436528039Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care.Lancet Respir Med2023https://conductscience.org/library/papers/36528039PubMed
1532445440Remdesivir for the Treatment of Covid-19 - Final Report.N Engl J Med2020https://conductscience.org/library/papers/32445440PubMed
1632284326Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.J Biol Chem2020https://conductscience.org/library/papers/32284326PubMed
1733264556Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.N Engl J Med2021https://conductscience.org/library/papers/33264556PubMed
1835740211Real-World Effectiveness and Optimal Dosage of Favipiravir for Treatment of COVID-19: Results from a Multicenter Observational Study in Thailand.Antibiotics (Basel)2022https://conductscience.org/library/papers/35740211PubMed
1921330339Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries.Am J Epidemiol2011https://conductscience.org/library/papers/21330339PubMed
2035396659WHO Ordinal Scale and Inflammation Risk Categories in COVID-19. Comparative Study of the Severity Scales.J Gen Intern Med2022https://conductscience.org/library/papers/35396659PubMed

See all 26 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
40465794In-hospital mortality outcomes of favipiravir in patients with moderate to severe COVID-19 infection: An emulated target trial using real-world data from the largest field hospital in Thailand.PLoS One2025https://conductscience.org/library/papers/40465794PubMed
38770366Remdesivir versus Favipiravir in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia: A Propensity Score-Matched Retrospective Cohort Study.Int J Gen Med2024https://conductscience.org/library/papers/38770366PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38770366

GET https://conductscience.org/api/papers/v1/38770366/references?page=2